Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H31NO3 |
| Molecular Weight | 357.4864 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CC#CCOC(=O)[C@](O)(C1CCCCC1)C2=CC=CC=C2
InChI
InChIKey=XIQVNETUBQGFHX-JOCHJYFZSA-N
InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3/t22-/m1/s1
DescriptionCurator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/12431028 | http://www.google.com/patents/WO1998000126A1 | https://www.ncbi.nlm.nih.gov/pubmed/7620236
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/12431028 | http://www.google.com/patents/WO1998000126A1 | https://www.ncbi.nlm.nih.gov/pubmed/7620236
Esoxybutynin is (S)-enantiomer of oxybutynin. Esoxybutynin exerts antimuscarinic properties. Racemic oxybutynin is used clinically to treat urinary incontinence. Sepracor was developing (S)-oxybutynin, a single-isomer version of Alza's Ditropan (racemic oxybutynin), a muscarinic acetylcholine receptor antagonist, as a potential treatment for urinary incontinence.
Originator
Approval Year
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
24.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11939551 |
ESOXYBUTYNIN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Augmentation ureterocystoplasty in bladder exstrophy: 5-year follow-up in two cases. | 2002 Dec |
|
| Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. | 2003 Jun |
|
| Oxybutynin extended-release: a review of its use in the management of overactive bladder. | 2004 |
|
| Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder. | 2004 Oct |
|
| [Urinary incontinence: anticholinergic treatment]. | 2004 Oct-Dec |
|
| A peripheric neuromodulation technique for curing detrusor overactivity: Stoller afferent neurostimulation. | 2005 |
|
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
| Influence of micro-environmental pH on the gel layer behavior and release of a basic drug from various hydrophilic matrices. | 2005 Mar 21 |
|
| Canadian Urological Association guidelines on urinary incontinence. | 2006 Jun |
|
| New transdermal bioadhesive film containing oxybutynin: In vitro permeation across rabbit ear skin. | 2006 Nov 15 |
|
| Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study. | 2006 Oct |
|
| Formulation and optimization of porous osmotic pump-based controlled release system of oxybutynin. | 2007 Jul 13 |
|
| Bladder augmentation: Review of the literature and recent advances. | 2007 Oct |
|
| Primary monosymptomatic nocturnal enuresis in children and adolescents. | 2007 Sep |
|
| Locked-in Syndrome in a Nigerian male with Multiple Sclerosis: a case report and literature review. | 2008 Oct 30 |
|
| Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial. | 2009 Nov |
|
| Application of oxybutynin selective sensors for monitoring the dissolution profile and assay of pharmaceutical dosage forms. | 2010 |
|
| Parasympathetic functions in children with sensory processing disorder. | 2010 |
|
| Medical management of overactive bladder. | 2010 Apr |
Sample Use Guides
from 100 mg to 1 000 mg/day. Phase IIB study, (S)-oxybutynin administered three times a day at 120 mg
Route of Administration:
Oral
Membrane currents were recorded from whole-cell configured guinea-pig and rabbit ventricular myocytes, and action potentials were recorded from guinea-pig and rabbit papillary muscles. L-type Ca(2+) current (I:(Ca,L)), rapidly-activating K(+) current (I:(Kr)) and slowly-activating K(+) current (I:(Ks)) were unaffected by submicromolar S-oxybutynin and inhibited by higher concentrations; IC(50) values were 17.8 microM for I:(Ca,L), 12 microM for I:(Kr), and 41 microM for I:(Ks).
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C166661
Created by
admin on Sat Dec 16 00:09:17 GMT 2023 , Edited by admin on Sat Dec 16 00:09:17 GMT 2023
|
PRIMARY | |||
|
DTXSID901317439
Created by
admin on Sat Dec 16 00:09:17 GMT 2023 , Edited by admin on Sat Dec 16 00:09:17 GMT 2023
|
PRIMARY | |||
|
300000036922
Created by
admin on Sat Dec 16 00:09:17 GMT 2023 , Edited by admin on Sat Dec 16 00:09:17 GMT 2023
|
PRIMARY | |||
|
206530
Created by
admin on Sat Dec 16 00:09:17 GMT 2023 , Edited by admin on Sat Dec 16 00:09:17 GMT 2023
|
PRIMARY | |||
|
8379
Created by
admin on Sat Dec 16 00:09:17 GMT 2023 , Edited by admin on Sat Dec 16 00:09:17 GMT 2023
|
PRIMARY | |||
|
51329
Created by
admin on Sat Dec 16 00:09:17 GMT 2023 , Edited by admin on Sat Dec 16 00:09:17 GMT 2023
|
PRIMARY | |||
|
CHEMBL1394756
Created by
admin on Sat Dec 16 00:09:17 GMT 2023 , Edited by admin on Sat Dec 16 00:09:17 GMT 2023
|
PRIMARY | |||
|
39EY4NVB8T
Created by
admin on Sat Dec 16 00:09:17 GMT 2023 , Edited by admin on Sat Dec 16 00:09:17 GMT 2023
|
PRIMARY | |||
|
119618-22-3
Created by
admin on Sat Dec 16 00:09:17 GMT 2023 , Edited by admin on Sat Dec 16 00:09:17 GMT 2023
|
PRIMARY |
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD
